Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Weinstock
Massachusetts Institute of Technology, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
Travera, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Travera, LLC is in the process of licensing from MIT the serial suspended microchannel resonator (SMR) technology developed by Scott Manalis. The overall grant aims to scale-up and validate the SMR, a novel microfluidic system that monitors the mass of individual cells within an MRD sample before and after delivery of a particular treatment. The Dana-Farber Cancer Institute Conflict of Interest Committee concluded that the results of this research could be of scientific and financial interest to Travera, LLC and, accordingly, represented a financial conflict of interest under the regulations.
Single cell growth assay for residual cells in acute lymphoblastic leukemia
Evidence that monitoring minimal residual disease (MRD) has prognostic value for acute lymphoblastic leukemias is becoming increasingly strong, however the primary roadblock between deep clinical response and cure for many patients has been the inability to therapeutically target MRD. We are proposing to scale-up and validate a novel microfluidic system that monitors the mass of individual MRD cells with unprecedented precision before and after delivery of a particular treatment. The primary deliverable of this R33 application is a system that can be used in clinical studies to address the following question: Does the growth response of a patient's cancer cells obtained at the time of MRD to a particular therapy predict that therapy's efficacy for that patient?
Filed on July 28, 2017.
Tell us what you know about David Weinstock's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Weinstock”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Weinstock | Dana Farber Cancer Inst | Conflict of Interest | Travera, LLC | Value cannot be readily determined |
| David Weinstock | Massachusetts Institute of Technology | Conflict of Interest | Travera, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.